e-therapeutics (LSE: ETX)

Currency in GBP

Last close As at 26/05/2023


0.25 (1.88%)

Market capitalisation


e-therapeutics is a UK biotech using its proprietary computational biology and RNAi platforms to discover novel disease targets and therapies. The company is specifically focused on leveraging its expertise to design treatments targeting one cell type in the liver, hepatocytes.

Latest Insights



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Ali Mortazavi


  • Laura Roca-Alonso

    Chief business officer

Balance Sheet

Forecast net debt (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.4 (20.6) (29.8)
Relative 4.2 (17.3) (29.5)
52 week high/low 23.0p/10.5p


e-therapeutics is a biotech leveraging its validated computational biology platform to identify novel, liver-associated targets and expand its internal pipeline of short interfering RNA (siRNA or RNAi) therapeutics. In addition to the advantages of focusing on a single cell type (hepatocytes), the company’s recent strategic commitment to large language model (LLM) technologies has the potential to provide accelerated access to effective new drugs. RNAi medicines are a rapidly evolving drug class, with five drugs currently that use this technology. We view RNAi as a key growth market for e therapeutics. At end-January 2023, the company had a net cash position of £31.7m, supported by a capital raise of £13.4m (net proceeds) in September 2022.

Y/E Jan Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2021A 0.3 (4.4) (4.5) (0.99) N/A N/A
2022A 0.5 (9.4) (9.5) (1.65) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free